Intellia Therapeutics, Inc. (NTLA)
- Previous Close
23.00 - Open
24.29 - Bid 24.81 x 100
- Ask 24.90 x 300
- Day's Range
23.35 - 24.94 - 52 Week Range
19.37 - 47.48 - Volume
1,609,526 - Avg. Volume
1,489,873 - Market Cap (intraday)
2.397B - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-5.42 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70.96
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
www.intelliatx.comRecent News: NTLA
Performance Overview: NTLA
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTLA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTLA
Valuation Measures
Market Cap
2.22B
Enterprise Value
1.42B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
56.28
Price/Book (mrq)
2.11
Enterprise Value/Revenue
39.18
Enterprise Value/EBITDA
-2.81
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.83%
Return on Equity (ttm)
-42.10%
Revenue (ttm)
36.27M
Net Income Avi to Common (ttm)
-481.19M
Diluted EPS (ttm)
-5.42
Balance Sheet and Cash Flow
Total Cash (mrq)
912.22M
Total Debt/Equity (mrq)
10.98%
Levered Free Cash Flow (ttm)
-268.21M
Research Analysis: NTLA
Company Insights: NTLA
NTLA does not have Company Insights